Trial Profile
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2014
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 May 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 18 Feb 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 07 Nov 2009 New trial record